查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1847924

RNA分析/轉錄組學市場（按產品、技術和應用）—全球預測 2025-2032

RNA Analysis/Transcriptomics Market by Product, Technology, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

RNA 分析/轉錄組學市場預計到 2032 年將成長到 134.6 億美元，複合年成長率為 10.79%。

主要市場統計數據
基準年2024年 59.2億美元
預計2025年 65.7億美元
預測年份：2032年 134.6億美元
複合年成長率（%） 10.79%

全面介紹在研究和臨床環境中影響 RNA 分析和轉錄組學的科學、操作和轉化力量

RNA分析和轉錄組學領域正處於關鍵的十字路口，在分子生物學、定序技術和計算分析技術的推動下，它們正在重新定義實驗和臨床方法。在過去幾年中，該領域已超越簡單的基因表現到為藥物開發、診斷和精密農業提供資訊的轉化應用。因此，研究和商業實驗室現在優先考慮整合的工作流程，以縮短從樣本到洞察的時間，同時提高可重複性和資料互通性。

在這種動態中，實驗室領導者和策略規劃人員必須平衡對重複性耗材、固定設備和軟體支援分析的投資。營運決策越來越取決於能否將濕實驗室通訊協定與強大的生物資訊流程（包括支援大型轉錄組學資料集的雲端原生解決方案）相協調。此外，相關人員的期望也在改變：資助者和監管機構要求透明的檢驗，臨床合作夥伴要求標準化的檢測方法，而出版機構則要求全面的元資料和可重複的流程。總而言之，RNA分析領域正在獎勵那些將卓越的技術與嚴謹的營運、全面的數據管理以及清晰的轉換藍圖相結合以連接髮現和應用的機構。

高通量測序、單細胞創新和軟體主導的生態系統的融合如何重新定義轉錄組學的營運重點和商業模式

轉錄組學領域正在經歷一場變革性的轉變，這不僅反映了技術的成熟度，也反映了終端使用者需求的變化。從技術角度來看，定序通量的提高和每個樣本處理時間的縮短，使得單細胞方法和高內涵批量研究得以廣泛應用，促使實驗室重新思考實驗設計，以便對生物系統進行更深入、更細緻的研究。同時，數位PCR和改進的即時PCR方法繼續為靶向檢測提供快速、靈敏的選擇，支援需要在基因組範圍內進行定量準確性的診斷和驗證工作流程。

同樣重要的是實驗室自動化、新型微流體平台和機器學習主導的分析的融合，它們共同實現了更高的吞吐量和更可重複的數據生成。這種整合正在將價值從獨立儀器轉移到耦合的生態系統，其中耗材、儀器韌體和分析軟體共同最佳化。經營模式正在相應調整。以訂閱和服務為中心的軟體和雲端分析方法正變得越來越突出，而製造商則優先考慮針對臨床和法規環境的經過驗證的端到端解決方案。此外，隨著協力網路和多站點研究的擴展，資料交換、品管和檢測檢驗的標準變得越來越重要，從而創造了一個互通性和合規性作為關鍵競爭優勢的環境。

評估近期美國關稅行動對轉錄組學全球採購、供應彈性和平台選擇的累積營運和策略影響

美國近期的貿易政策發展和關稅行動導致全球RNA分析所需的實驗室設備、試劑及相關組件的供應鏈重新調整。依賴跨國採購的公司和機構經歷了籌資策略的轉變，擴大了供應商資格認證流程，並更加重視庫存彈性。關稅相關的成本壓力促使製造商評估替代採購、本地化某些生產過程，並重新協商供應商契約，以維持淨利率並確保供應的連續性。

在營運方面，這些變更表現前置作業時間延長，採購團隊設立了緊急庫存和多樣化的供應商清單，以減少中斷。研究小組調整了採購順序，以減少與進口相關的延誤風險，在某些情況下，他們選擇了本地服務覆蓋範圍更廣的平台。從產品開發的角度來看，正在加速推進可製造設計，以減少對地緣政治敏感部件的依賴，並實現跨地區的模組化採購。

此外，關稅的累積影響正在推動供應商和經銷商之間建立策略夥伴關係，以促進海關合規並簡化物流流程。這些合作通常包括對區域倉庫的共同投資、統一的文件流程以及擴展的現場服務網路。對於轉化研究和臨床測試部署而言，最終效果是更加重視供應鏈透明度、供應商管理和合約保障，從而協調採購和營運風險接受度。展望未來，相關人員可能會繼續優先考慮採購決策的韌性和靈活性，同時密切關注可能改變關鍵臨床測試投入跨境貿易動態的政策變化。

深度細分分析，說明不同的產品、技術和應用途徑如何在轉錄組學工作流程中產生差異化的需求訊號和研發重點

細緻的細分觀點揭示了RNA分析中每種產品、技術和應用的獨特需求促進因素和採用障礙。按產品類型分類，對耗材和試劑的持續需求支撐著實驗室的連續性，對於需要穩定批間性能和可靠供應的最終用戶而言，這仍然是核心營運重點。儀器仍然是資本配置決策的關鍵，因為平台選擇會影響通量、檢測相容性和下游資料特性。互補的軟體和服務構成了將原始測量數據轉化為可操作知識的紐帶，從而支持標準化、合規性和多中心研究的可擴展分析。

從技術角度來看，該生態系統包括數位PCR和即時PCR，它們是用於標靶定量和檢驗的強大工具，而微陣列技術則在特定的比較表達研究中佔據一席之地。次世代定序儀已成為主流的高解析度方法，批量轉錄組學可滿足廣泛的發現用例，而單細胞轉錄組學則能夠研究異質組織和稀有細胞類型。同時，基於微流體的平台可為專門的偵測和多組體學整合提供精確控制。每種技術類別都有不同的樣品製備要求、計算需求和品管基準，從而影響各組織之間的採用曲線。

應用主導的細分進一步明確了優先順序。癌症研究持續需要深度轉錄組分析來闡明腫瘤異質性和治療抗藥性機制，而藥物研發則利用表達特徵和通路分析來識別標靶並進行動態。基因檢測項目需要涵蓋攜帶者篩檢、疾病診斷以及產前和新生兒應用的強大且經過驗證的檢測方法，尤其注重檢測方法的靈敏度、特異性和監管準備度。感染疾病研究需要快速、靈敏的檢測方法和可擴展的定序來追蹤病原體和宿主的反應，而植物研究也擴大採用轉錄組工具來加速性狀發現和壓力反應表徵。了解這些相互交叉的細分軸，使公司能夠根據每個用戶群體的細微需求自訂產品系列、研發投資和商業策略。

區域動態和基礎設施現實將影響世界不同地區的轉錄組學採用途徑、夥伴關係策略和監管協調

區域動態反映了研究資金、監管格局、產業環境和臨床基礎設施的差異，決定了轉錄組學工具和服務的採用、支持和商業化方式。在美洲，由學術中心、生物技術公司和臨床實驗室組成的密集生態系統正在推動先進定序平台和單細胞技術的早期應用，轉化研究與商業性創新之間有著密切的聯繫。這種環境催生了一個競爭激烈的服務供應商領域，支援快速技術檢驗、策略聯盟以及從發現到臨床級檢測的規模化擴展。

歐洲、中東和非洲地區的採用模式各不相同。主要的卓越中心和國家級舉措加速了高通量平台和標準化工作流程的採用，而更廣泛的地區差異則反映了資金和實驗室基礎設施取得的差異。歐洲法律規範特別強調臨床驗證和資料隱私，供應商則強調合規性和在地化支援。同時，合作聯盟和廣泛地區計劃有助於傳播最佳實踐，並實現高成本技術的資源共用。

在亞太地區，公共和私人對生命科學的投資不斷成長，推動了對設備和耗材的需求。新興經濟體正在發展國內製造和服務能力，這影響了採購偏好和價格敏感度。研究機構和臨床基因組學計畫的快速發展，推動了製藥、農業和公共衛生領域的應用。這些區域動態的結合需要差異化的商業策略。跨國供應商必須根據當地的監管要求、基礎設施成熟度和客戶支援期望，客製化其市場進入方式、服務模式和夥伴關係。

解決方案供應商之間的競爭行為、整合策略和能力優先順序決定了轉錄組學領域的供應商選擇和夥伴關係機會

RNA分析和轉錄組學價值鏈上的公司活動體現了技術差異化、服務擴展和策略整合的融合。儀器製造商持續在通量、準確性和易用性方面競爭，而試劑製造商則強調穩健的化學過程、批次一致性和經過驗證的工作流程，以降低檢驗的差異性。同時，分析服務供應商和軟體供應商正在加速對雲端原生平台、標準化流程和解釋層的投資，以滿足研究和臨床報告的需求。

策略行動包括有針對性的併購，以確保專有的化學和分析資產；基於夥伴關係關係的上市方式，將儀器與耗材和資訊服務捆綁在一起；以及擴展現場服務網路以支持全球擴張。成功整合硬體、化學和軟體的公司通常能夠透過減輕最終用戶的檢驗負擔並加快洞察時間而獲得競爭優勢。相反，專注於利基分析化學、微流體創新和先進生物資訊學的專業供應商可以透過與平台供應商和受託研究機構的合作來獲取價值。

對於客戶而言，供應商選擇如今包括評估長期支援、互通性以及檢驗應用的廣度。採購決策也擴大考慮藍圖透明度、監管準備以及培訓和應用支援的可用性。不斷變化的競爭格局有利於那些能夠展示可重複性、全面的檢驗資料集以及在產業中實現臨床轉化和規模化推廣的實用途徑的組織。

領導者建構彈性供應鏈、可互通的生態系統和臨床適用的轉錄組學產品的策略要務

產業領導者應採取積極主動的立場，強調其產品和業務組合的彈性、互通性和轉化準備度。首先，組織藍圖必須優先考慮濕實驗室團隊、生物資訊部門和採購部門之間的跨職能協作，以確保平台選擇既能帶來即時的實驗效益，又能實現長期的可擴展性。投資決策應優先考慮模組化解決方案，這些解決方案能夠實現增量容量擴展，並在不犧牲檢驗效能的情況下最大限度地減少對專有組件的鎖定。

其次，企業應注重供應鏈透明度和多元化採購，以降低地緣政治和關稅相關風險。這包括篩選合格的替代供應商，確保關鍵試劑的策略性庫存緩衝，以及協商明確前置作業時間和支援的服務水準協議。第三，供應商和服務供應商應強調開放標準、通用資料格式和檢驗的API，以促進儀器、實驗室資訊管理系統（LIMS）和分析平台之間的互通性，並降低最終用戶的整合成本。

第四，商業團隊應圍繞以結果為導向的價值提案建構其產品，將儀器、檢驗的耗材和分析服務結合。對於轉化舉措，公司應建立或與強大的臨床檢驗途徑、監管專業知識以及符合認證要求的可重複文件合作。最後，領導者應投資於人才培養——包括培訓計畫、方法學研討會和應用支援——以幫助客戶充分發揮轉錄組學技術的潛力，同時保持高標準的數據品質和檢測可重複性。

結合相關人員訪談、技術基準化分析和情境分析的穩健混合方法研究設計，確保轉錄組學相關人員獲得可複製和可操作的見解

本研究整合了來自相關人員、技術文獻和已驗證技術評估的原始資訊，旨在對RNA分析和轉錄組學的發展趨勢進行全面的、基於證據的分析。原始數據透過與實驗室主任、採購專家和技術開發人員進行結構化訪談收集，並輔以供應商藍圖和同行評審的、記錄檢測性能和可重複性的方法學研究。二級資訊來源包括技術白皮書、監管指南文件以及說明工作流程效率和驗證要求的基準研究。

此分析方法將相關人員訪談的定性主題編碼與比較技術分析和基於場景的供應鏈分析相結合。關鍵效能屬性，例如檢測靈敏度、通量、工作流程複雜性和運算要求，被映射到不同產品和技術類別中，突出相容性限制和可行能力。在適當的情況下，我們運用案例和實際工作實務來說明研究機構如何進行平台選擇和部署。在整個過程中，研究結果透過專家評審週期進行交叉檢驗，以確保技術準確性以及與研究和臨床應用的實際相關性。

整合策略重點，強調轉錄組學中的技術能力、運作彈性和轉化準備之間的相互作用

總而言之，RNA分析和轉錄組學正在從探索性科學轉型為一個綜合領域，技術選擇、資料管理和供應鏈彈性共同決定研究和轉化的成功。單細胞和高通量定序的進步正在釋放新的生物學洞見，但它們的未來取決於嚴謹的工作流程、可互通的檢測方法以及可靠的試劑和服務生態系統。對於尋求持續生產力的研究機構而言，跨多元化採購的營運彈性、清晰的供應商支援和檢驗的通訊協定與技術能力同等重要。

展望未來，那些將耗材、設備和分析方面的投資與可重複性和合規性相結合的相關人員，將最有能力將發現轉化為實際影響。製造商、服務供應商和最終用戶之間的合​​作將加速檢驗途徑，並降低臨床應用的門檻。最終，最成功的組織將是那些不僅將轉錄組學視為單一技術選擇，而是將其視為一種系統級能力的組織，這種能力將整合實驗室實踐、計算嚴謹性和供應鏈規範，從而提供可靠、可操作的生物學見解。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 利用長讀長RNA定序對全長異構體進行大規模分析
  • 整合成像和基因表現的空間轉錄組學技術快速發展
  • 擴展結合轉錄組分析和表觀遺傳學數據的單細胞多體學學分析
  • 實現人工智慧驅動的高通量轉錄組學數據解釋分析平台
  • 直接 RNA定序方法的興起，可以偵測天然轉錄本上的修飾
  • 開發用於可擴展單細胞轉錄組學研究的高密度微流體平台
  • 液態生物檢體轉錄組學在微創癌症生物標記發現的進展
  • 標準化基於雲端基礎的管道，用於大型轉錄組學資料集的協作分析
  • 將 CRISPR篩檢與轉錄組分析結合以識別功能基因標靶
  • 個人化腫瘤診斷對臨床級轉錄組學檢測的需求不斷成長

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. RNA分析/轉錄組學市場（按產品）

  • 耗材和試劑
  • 裝置
  • 軟體和服務

9. RNA分析/轉錄組學市場（按技術）

  • 數位PCR
  • 微陣列
  • 次世代定序
    • 批量轉錄組學
    • 單細胞轉錄組學
      • 基於液滴
      • 基於微流體
  • 即時PCR

第 10 章 RNA 分析/轉錄組學市場（按應用）

  • 癌症研究
  • 藥物研發
  • 基因檢測
    • 攜帶者篩檢
    • 疾病診斷
    • 產前和新生兒檢測
  • 感染疾病監測
  • 植物調查

第 11 章 RNA 分析/轉錄組學市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 12 章：RNA 分析/轉錄組學市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 13 章 RNA 分析/轉錄組學市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Illumina, Inc.
    • Thermo Fisher Scientific Inc.
    • QIAGEN NV
    • Agilent Technologies, Inc.
    • Bio-Rad Laboratories, Inc.
    • Roche Diagnostics International AG
    • Pacific Biosciences of California, Inc.
    • Oxford Nanopore Technologies Ltd.
    • Takara Bio Inc.
    • 10x Genomics, Inc.
Product Code: MRR-FB6C9E7932C7

The RNA Analysis/Transcriptomics Market is projected to grow by USD 13.46 billion at a CAGR of 10.79% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.92 billion
Estimated Year [2025] USD 6.57 billion
Forecast Year [2032] USD 13.46 billion
CAGR (%) 10.79%

A comprehensive primer on the scientific, operational, and translational forces reshaping RNA analysis and transcriptomics across research and clinical domains

The field of RNA analysis and transcriptomics is at a pivotal juncture, driven by advances in molecular biology, sequencing technologies, and computational analytics that together are redefining experimental and clinical approaches. Over the past several years, the community has moved beyond simple gene expression snapshots to adopt high-resolution, scalable methods that capture cellular heterogeneity, temporal dynamics, and regulatory complexity. As a result, research priorities have expanded from foundational discovery to translational applications that inform drug development, diagnostics, and precision agriculture. Consequently, institutions and commercial laboratories now prioritize integrated workflows that reduce time from sample to insight while increasing reproducibility and data interoperability.

Given these dynamics, laboratory leaders and strategic planners must balance investments across recurring consumables, capital instrumentation, and software-enabled analytics. Operational decisions increasingly hinge on the ability to harmonize wet-lab protocols with robust bioinformatics pipelines, including cloud-native solutions that support large-scale transcriptomics datasets. Moreover, stakeholder expectations have shifted: funders and regulators demand transparent validation, clinical partners need standardized assays, and publishing outlets require comprehensive metadata and reproducible pipelines. In sum, the RNA analysis landscape now rewards organizations that combine technological excellence with operational rigor, comprehensive data stewardship, and clear translational roadmaps that bridge discovery and application.

How converging high-throughput sequencing, single-cell innovations, and software-driven ecosystems are redefining operational priorities and commercial models in transcriptomics

The landscape of transcriptomics is undergoing transformative shifts that reflect both technological maturation and changing end-user requirements. Technologically, improvements in sequencing throughput and reductions in per-sample processing times have enabled broader adoption of single-cell approaches and high-content bulk studies, prompting laboratories to rethink experimental design toward deeper, more granular interrogation of biological systems. Concurrently, digital PCR and refined real-time PCR methods continue to provide rapid, high-sensitivity options for targeted assays, supporting diagnostics and validation workflows that require quantitative precision rather than genome-scale breadth.

Equally important is the convergence of laboratory automation, novel microfluidic platforms, and machine learning-driven analytics, which together permit higher throughput and more reproducible data generation. This integration is shifting value from standalone instruments to coupled ecosystems where consumables, instrument firmware, and analytical software are co-optimized. Business models are adapting in response: subscription and service-centric approaches for software and cloud analytics are becoming more prominent, while manufacturers emphasize validated end-to-end solutions for clinical and regulated environments. Additionally, as collaborative networks and multi-site studies grow, standards for data exchange, quality control, and assay validation are becoming more consequential, fostering an environment where interoperability and compliance are critical competitive differentiators.

Assessing the cumulative operational and strategic consequences of recent United States tariff actions on global procurement, supply resilience, and platform selection in transcriptomics

Recent trade policy developments and tariff actions in the United States have created a recalibration across global supply chains for laboratory equipment, reagents, and related components that support RNA analysis. Companies and institutions reliant on cross-border sourcing have experienced shifts in procurement strategies, prompting extended supplier qualification processes and increased emphasis on inventory resilience. Tariff-related cost pressures have incentivized manufacturers to evaluate alternative sourcing, localize certain production steps, and renegotiate supplier contracts to preserve margin and ensure continuity of supply.

Operationally, these changes have manifested as elongated lead times for specific instrument components and specialized reagents, with procurement teams instituting contingency inventories and diversified vendor lists to mitigate disruption. Research groups have adjusted procurement cadence and, in some cases, selected platforms with broader local service footprints to reduce exposure to import-related delays. From a product-development perspective, firms are accelerating design for manufacturability initiatives that reduce reliance on geopolitically sensitive parts and that enable modular sourcing across multiple regions.

Furthermore, the cumulative effect of tariff measures has driven strategic partnerships between suppliers and distributors to smooth customs compliance and to streamline logistics. These collaborations often include co-investment in regional warehousing, harmonized documentation processes, and expanded field service networks. For translational research and clinical assay deployment, the net impact includes a greater emphasis on supply-chain transparency, vendor management, and contractual safeguards that align procurement with operational risk tolerance. Looking forward, stakeholders are likely to continue prioritizing resilience and flexibility in sourcing decisions while monitoring policy shifts that could alter cross-border trade dynamics for critical laboratory inputs.

Deep segmentation analysis explaining how distinct product, technology, and application pathways create differentiated demand signals and R&D priorities across transcriptomics workflows

A granular segmentation perspective reveals differentiated demand drivers and adoption barriers across products, technologies, and applications in RNA analysis. When viewed by product type, recurring demand for consumables and reagents underpins laboratory continuity and represents a central operational priority for end users who require consistent lot-to-lot performance and supply reliability. Instruments remain a critical focal point for capital allocation decisions because platform selection dictates throughput, assay compatibility, and downstream data characteristics. Complementary software and services form the connective tissue that converts raw measurements into actionable knowledge, enabling standardization, regulatory compliance, and scalable analytics for multi-site studies.

By technology, the ecosystem includes digital PCR and real-time PCR as robust tools for targeted quantification and validation, while microarray technologies retain a niche for specific comparative expression studies. Next Generation Sequencing has emerged as the dominant high-resolution approach, with bulk transcriptomics serving broad discovery use cases and single cell transcriptomics enabling interrogation of heterogeneous tissues and rare cell types. Within single-cell studies, droplet-based methods provide high-throughput cell partitioning suitable for large-scale atlasing projects, whereas microfluidics-based platforms offer precise control for specialized assays and multiomic integrations. Each technological class carries distinct workflow implications: sample preparation requirements, computational needs, and quality control benchmarks vary and therefore influence adoption curves across organizations.

Application-driven segmentation further clarifies prioritization. Cancer research continues to demand deep transcriptomic profiling to elucidate tumor heterogeneity and therapeutic resistance mechanisms, while drug discovery leverages expression signatures and pathway analyses for target identification and pharmacodynamics. Genetic testing programs require robust, validated assays across carrier screening, disease diagnostics, and prenatal and newborn applications, with particular emphasis on assay sensitivity, specificity, and regulatory readiness. Infectious disease research relies on rapid, high-sensitivity assays and scalable sequencing to track pathogens and host responses, and plant research increasingly adopts transcriptomic tools to accelerate trait discovery and stress-response characterization. Understanding these intersecting segmentation axes helps organizations align product portfolios, R&D investments, and commercial strategies to the nuanced needs of each user community.

Regional dynamics and infrastructure realities that determine adoption pathways, partnership strategies, and regulatory alignment for transcriptomics across global geographies

Regional dynamics shape how transcriptomics tools and services are adopted, supported, and commercialized, reflecting differences in research funding, regulatory landscapes, industrial partnerships, and clinical infrastructure. In the Americas, a dense ecosystem of academic centers, biotech companies, and clinical laboratories drives early adoption of advanced sequencing platforms and single-cell technologies, with strong ties between translational research and commercial innovation. This environment fosters rapid technology validation, strategic collaborations, and a competitive service-provider sector that supports scaling from discovery to clinical-grade assays.

Across Europe, the Middle East, and Africa, adoption patterns are heterogeneous: leading research hubs and national initiatives accelerate uptake of high-throughput platforms and standardized workflows, while broader regional disparities reflect variable access to capital and laboratory infrastructure. Regulatory frameworks in some European jurisdictions place particular emphasis on clinical validation and data privacy, prompting suppliers to emphasize compliance and localized support. Meanwhile, collaborative consortia and pan-regional projects help disseminate best practices and enable resource-sharing for high-cost technologies.

In the Asia-Pacific region, expanding public and private investment in life sciences has elevated demand for both instruments and consumables. Several countries are developing strong domestic manufacturing and service capabilities, which influences procurement preferences and price sensitivity. Rapidly growing research communities and clinical genomics programs are driving adoption across pharmaceutical, agricultural, and public health domains. Taken together, these regional dynamics necessitate differentiated commercial strategies: multinational suppliers must tailor go-to-market approaches, service models, and partnerships to align with local regulatory requirements, infrastructure maturity, and customer support expectations.

Competitive behaviors, integration strategies, and capability priorities among solution providers that determine vendor selection and partnership opportunities in transcriptomics

Company activity across the RNA analysis and transcriptomics value chain reflects a blend of technological differentiation, service expansion, and strategic consolidation. Instrument manufacturers continue to compete on throughput, accuracy, and ease of use, while reagent suppliers focus on robust chemistry, lot consistency, and validated workflows that reduce assay variability. At the same time, analytics providers and software vendors are accelerating investments in cloud-native platforms, standardized pipelines, and interpretive layers that address both research and clinical reporting needs.

Strategic behaviors include targeted M&A to secure proprietary chemistries or analytics assets, partnership-based go-to-market approaches that bundle instruments with consumables and data services, and expanded field service networks to support global deployment. Companies that successfully integrate hardware, chemistry, and software often gain a competitive edge by reducing end-user validation burden and enabling faster time to insight. Conversely, specialist providers that focus on niche assay chemistries, microfluidic innovations, or advanced bioinformatics can capture value through collaborations with platform vendors and contract research organizations.

For customers, vendor selection now involves assessment of long-term support, interoperability, and the breadth of validated applications. Procurement decisions increasingly weigh roadmap transparency, regulatory readiness, and the availability of training and application support. The evolving competitive landscape favors organizations that can demonstrate demonstrable reproducibility, comprehensive validation datasets, and pragmatic pathways for clinical translation or industrial scale-up.

Actionable strategic imperatives for leaders to build resilient supply chains, interoperable ecosystems, and clinically translatable transcriptomics offerings

Industry leaders should adopt a proactive stance that emphasizes resilience, interoperability, and translational readiness across product and operational portfolios. First, organizational roadmaps must prioritize cross-functional alignment between wet-lab teams, bioinformatics units, and procurement to ensure that platform selections deliver both immediate experimental benefits and long-term scalability. Investment decisions should favor modular solutions that allow incremental expansion of capacity and that minimize lock-in to proprietary components without sacrificing validated performance.

Second, firms should double down on supply-chain transparency and diversified sourcing to mitigate geopolitical and tariff-related risks. This includes qualifying alternative suppliers, securing strategic inventory buffers for critical reagents, and negotiating service-level agreements that provide clarity on lead times and support. Third, vendors and service providers should emphasize open standards, common data formats, and validated APIs to facilitate interoperability across instruments, LIMS, and analytics platforms, reducing integration overhead for end users.

Fourth, commercial teams should structure offerings around outcome-focused value propositions that combine instrumentation, validated consumables, and analytics services. For translational initiatives, companies must build or partner for robust clinical validation pathways, regulatory expertise, and reproducible documentation that meet certification requirements. Finally, leaders should invest in workforce enablement-training programs, methodological workshops, and application support-to ensure that customers realize the full potential of transcriptomics technologies while maintaining high standards of data quality and assay reproducibility.

Robust mixed-methods research design combining stakeholder interviews, technical benchmarking, and scenario analyses to ensure reproducible and actionable insights for transcriptomics stakeholders

This research synthesized primary stakeholder input, technical literature, and validated technology assessments to produce a comprehensive, evidence-based analysis of RNA analysis and transcriptomics trends. Primary data were gathered through structured interviews with laboratory directors, procurement specialists, and technology developers, complemented by vendor roadmaps and peer-reviewed methodological studies that document assay performance and reproducibility. Secondary sources included technical white papers, regulatory guidance documents, and benchmarking studies that describe workflow efficiencies and validation requirements.

Analytical methods combined qualitative thematic coding of stakeholder interviews with comparative technology profiling and scenario-based supply-chain analysis. Key performance attributes-such as assay sensitivity, throughput, workflow complexity, and computational requirements-were mapped across product and technology segments to highlight compatibility constraints and enabling capabilities. Where appropriate, case examples and real-world operational practices were used to illustrate how institutions navigate platform selection and deployment. Throughout the process, findings were cross-validated via expert review cycles to ensure technical accuracy and practical relevance for both research and clinical audiences.

Synthesis of strategic priorities highlighting the interplay of technological capability, operational resilience, and translational readiness in transcriptomics

In conclusion, RNA analysis and transcriptomics are transitioning from exploratory science to an integrated field where technological selection, data stewardship, and supply-chain resilience jointly determine research and translational success. Advances in single-cell and high-throughput sequencing are unlocking new biological insights, yet their promise depends on rigorous workflows, interoperable analytics, and reliable reagent and service ecosystems. Operational resilience-spanning diversified sourcing, clear vendor support, and validated protocols-has become as important as technical capability for institutions seeking sustained productivity.

Looking ahead, stakeholders that align investments across consumables, instruments, and analytics while maintaining a focus on reproducibility and regulatory readiness will be best positioned to translate discovery into impact. Collaboration between manufacturers, service providers, and end users will accelerate validation pathways and lower barriers to clinical adoption. Ultimately, the most successful organizations will be those that treat transcriptomics not as a single technology choice but as a systems-level capability that integrates laboratory practice, computational rigor, and supply-chain discipline to deliver reliable, actionable biological insights.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of long-read RNA sequencing to resolve full-length transcript isoforms at scale
  • 5.2. Rapid growth of spatial transcriptomics techniques integrating imaging and gene expression
  • 5.3. Expansion of single-cell multiomics assays coupling transcriptome profiling with epigenetic data
  • 5.4. Implementation of AI-driven analytics platforms for high-throughput transcriptomic data interpretation
  • 5.5. Rise of direct RNA sequencing approaches enabling native transcript modifications detection
  • 5.6. Development of high-density microfluidic platforms for scalable single-cell transcriptomic studies
  • 5.7. Advancements in liquid biopsy transcriptomics for minimally invasive cancer biomarker discovery
  • 5.8. Standardization of cloud-based pipelines for collaborative analysis of large transcriptomics datasets
  • 5.9. Integration of CRISPR screening with transcriptome profiling for functional gene target identification
  • 5.10. Growing demand for clinical-grade transcriptomics assays in personalized oncology diagnostics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RNA Analysis/Transcriptomics Market, by Product

  • 8.1. Consumables & Reagents
  • 8.2. Instruments
  • 8.3. Software & Services

9. RNA Analysis/Transcriptomics Market, by Technology

  • 9.1. Digital PCR
  • 9.2. Microarray
  • 9.3. Next Generation Sequencing
    • 9.3.1. Bulk Transcriptomics
    • 9.3.2. Single Cell Transcriptomics
      • 9.3.2.1. Droplet Based
      • 9.3.2.2. Microfluidics Based
  • 9.4. Real Time PCR

10. RNA Analysis/Transcriptomics Market, by Application

  • 10.1. Cancer Research
  • 10.2. Drug Discovery
  • 10.3. Genetic Testing
    • 10.3.1. Carrier Screening
    • 10.3.2. Disease Diagnostics
    • 10.3.3. Prenatal & Newborn Testing
  • 10.4. Infectious Disease Research
  • 10.5. Plant Research

11. RNA Analysis/Transcriptomics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. RNA Analysis/Transcriptomics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. RNA Analysis/Transcriptomics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Illumina, Inc.
    • 14.3.2. Thermo Fisher Scientific Inc.
    • 14.3.3. QIAGEN N.V.
    • 14.3.4. Agilent Technologies, Inc.
    • 14.3.5. Bio-Rad Laboratories, Inc.
    • 14.3.6. Roche Diagnostics International AG
    • 14.3.7. Pacific Biosciences of California, Inc.
    • 14.3.8. Oxford Nanopore Technologies Ltd.
    • 14.3.9. Takara Bio Inc.
    • 14.3.10. 10x Genomics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. RNA ANALYSIS/TRANSCRIPTOMICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. RNA ANALYSIS/TRANSCRIPTOMICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. RNA ANALYSIS/TRANSCRIPTOMICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 135. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 136. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 137. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 138. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 150. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 164. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 206. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 208. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 220. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 221. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 250. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 251. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 261. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 264. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 265. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 267. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 268. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 269. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 270. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 271. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 272. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 273. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 274. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 292. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 293. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2025-2032